Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A New Solution for the Multibillion-Dollar Bladder Cancer Problem

Bladder cancer is the sixth-most prevalent cancer in North America and has a recurrence rate greater than 50%, making it the most expensive cancer to treat. All-in costs in the US are around $4 billion and roughly 80,000 new American cases are reported each year, with 350,000...
Stockhouse Editorial | May 25, 2020 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

The promise of AI

In ‘The Terminator’ series of action films starring Arnold Schwarzenegger, a cybernetic organism (cyborg) is programmed from the future to go back in time and kill the mother of the scientist who leads the fight against Skynet, an artificial intelligence syst...
Richard (Rick) Mills | November 22, 2019 |

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. Eli Lilly and Co. (LLY:NYSE) today annou...
Streetwise Reports | June 17, 2020 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. In a Feb. 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that CytoDyn Inc. (CYDY:OTCQB) plans to...
Streetwise Reports | March 1, 2019 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer ...

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.' Imagin Medical Inc. (IME:CSE; ...
Streetwise Reports | January 15, 2020 |
1 2 3 4 5 6 7 8 9 10 ...